Medigen Biotechnology Corp (3176)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013563)
◆英語タイトル:Medigen Biotechnology Corp (3176) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013563
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:40
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Medigen Biotechnology Corp (MBC) is a pharmaceutical company that carries out the research and development of biopharmaceuticals for the treatment of liver diseases and cancers. It focuses at developing new therapeutics, principally in the area of cancer and liver diseases. The company’s product portfolio includes monoclonal antibodies; vaccines; molecular diagnostics and generic drugs. MBC also provides original equipment manufacturing (OEM) and original design manufacturing (ODM) manufacturing services in various dosage forms including orals, externals, ophthalmic and hormones; nutrition supplements; cosmeceutical products. ’s subsidiaries include Medigen Vaccine Biologics; TBG Biotechnology Corp.; and Winston Medical Supply Co., Ltd. MBC is headquartered in Taipei city, Taiwan.

Medigen Biotechnology Corp (3176) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Medigen Biotechnology Corp, Medical Devices Deals, 2011 to YTD 2017 10
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Medigen Biotech Acquires B-cell Immortalization Platform Technology 13
Partnerships 14
Medigen Biotech to Form Joint Venture for Vaccine Technology 14
Licensing Agreements 15
Medigen Vaccine Biologics Expands Licensing Agreement with National Institutes of Health for Dengue Vaccine 15
Medigen Vaccine Biologics Enteres into Licensing Agreement with National Health Research Institutes 16
Progen Pharma To Enter Into Licensing Agreement With Medigen Biotech For PG545 17
Equity Offering 18
Medigen Vaccine Biologics to Raise Up to USD15.8 Million in Private Placement of Shares 18
Medigen Vaccine Biologics to Raise up to USD13.5 Million in Private Placement of Shares 19
Medigen Vaccine Biologics Raises USD13.5 Million in Rights Offering of Shares 20
Medigen Biotech to Raise Funds in Public Offering of Shares 21
Medigen Vaccine Biologics Raises USD28.8 Million in IPO 22
Medigen Biotech Completes Public Offering Of Shares For US$4 Million 23
Medigen Biotech Completes Rights Offering Of Shares For US$32 Million 24
Medigen Biotech Announces Rights Offering Of Shares For US$21 Million 25
Medigen Biotech Announces Public Offering Of Shares For US$2.7 Million 26
Medigen Biotech Prices Public Offering Of Common Stock For US$10 Million 27
Acquisition 28
United Microelectronics Acquires 8% Stake in Medigen for USD4 Million 28
Medigen Biotech To Acquire 67.92% Stake In Winston Medical 29
PerkinElmer Acquires Shanghai Haoyuan Biotech From Medigen Biotech For US$38 Million 30
Medigen Biotech Acquires Remaining Stake In Texas BioGene 32
Medigen Biotechnology Corp – Key Competitors 33
Medigen Biotechnology Corp – Key Employees 34
Medigen Biotechnology Corp – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Strategy And Business Planning 36
Nov 23, 2016: Medigen Vaccine Biologics’s Inaugurates Taiwan’s First Cell-Based Vaccine Manufacturing Plant 36
Product News 37
Dec 09, 2016: MVC Teamed with US CDC to develop VLP Vaccine for Dengue Disease 37
Nov 15, 2016: National Health Insurance (NHI) granted two Winston’s product with NHI drug price 38
Other Significant Developments 39
Oct 19, 2017: MVC co-organized international forum for dengue prevention and vaccine development 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Medigen Biotechnology Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Medigen Biotechnology Corp, Medical Devices Deals, 2011 to YTD 2017 10
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Medigen Biotech Acquires B-cell Immortalization Platform Technology 13
Medigen Biotech to Form Joint Venture for Vaccine Technology 14
Medigen Vaccine Biologics Expands Licensing Agreement with National Institutes of Health for Dengue Vaccine 15
Medigen Vaccine Biologics Enteres into Licensing Agreement with National Health Research Institutes 16
Progen Pharma To Enter Into Licensing Agreement With Medigen Biotech For PG545 17
Medigen Vaccine Biologics to Raise Up to USD15.8 Million in Private Placement of Shares 18
Medigen Vaccine Biologics to Raise up to USD13.5 Million in Private Placement of Shares 19
Medigen Vaccine Biologics Raises USD13.5 Million in Rights Offering of Shares 20
Medigen Biotech to Raise Funds in Public Offering of Shares 21
Medigen Vaccine Biologics Raises USD28.8 Million in IPO 22
Medigen Biotech Completes Public Offering Of Shares For US$4 Million 23
Medigen Biotech Completes Rights Offering Of Shares For US$32 Million 24
Medigen Biotech Announces Rights Offering Of Shares For US$21 Million 25
Medigen Biotech Announces Public Offering Of Shares For US$2.7 Million 26
Medigen Biotech Prices Public Offering Of Common Stock For US$10 Million 27
United Microelectronics Acquires 8% Stake in Medigen for USD4 Million 28
Medigen Biotech To Acquire 67.92% Stake In Winston Medical 29
PerkinElmer Acquires Shanghai Haoyuan Biotech From Medigen Biotech For US$38 Million 30
Medigen Biotech Acquires Remaining Stake In Texas BioGene 32
Medigen Biotechnology Corp, Key Competitors 33
Medigen Biotechnology Corp, Key Employees 34
Medigen Biotechnology Corp, Other Locations 35
Medigen Biotechnology Corp, Subsidiaries 35

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Medigen Biotechnology Corp (3176)-製薬・医療分野:企業M&A・提携分析(Medigen Biotechnology Corp (3176) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆